SAN Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in Finland and Germany. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab; and antibody collaboration with Regeneron Pharmaceuticals, Inc. to develop antibodies, such as Dupixent (dupilumab) as treatment for diseases driven by type 2 inflammation. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.…
Industry Peers
Drug Manufacturers - GeneralKey Statistics
About Sanofi (EPA: SAN)
›
Sanofi (EPA: SAN) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 74,846 employees.
The shares were at 84.82 EUR on 20 November 2026, down 1.2% over 52 weeks. Its 52-week range is 69.75 EUR to 89.00 EUR: the price is 4.7% below the high and 21.6% above the low.
At a market capitalisation of 101.96B EUR, it trades at 24.5 times trailing earnings and 8.9 times forward earnings. The median trailing P/E of its 18 largest Drug Manufacturers - General peers is 26.1, so SAN is valued in line with them. It pays a dividend yielding 4.78% (it pays out 119% of its earnings), against a median of 2.45% among the dividend payers in that peer group.
Sanofi reports return on equity of 10.9%, an operating margin of 22.3% and revenue up 15.7% year over year.
Its debt exceeds its cash by 13.88B EUR, a debt-to-equity ratio of 0.28. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 23 analysts cover the stock, with an average rating of Buy; their mean price target of 96.36 EUR is 13.6% above the current price. The next earnings report is expected on 28 January 2027.